Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bosutinib - Georgetown University/ KeifeRx

Next Previous
Drug Profile

Bosutinib - Georgetown University/ KeifeRx

Alternative Names: KFRX-02

Latest Information Update: 28 Sep 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Georgetown University
  • Class Aniline compounds; Antidementias; Antineoplastics; Chlorine compounds; Nitriles; Piperazines; Quinolines; Small molecules; Urologics
  • Mechanism of Action Bcr-Abl tyrosine kinase inhibitors; Src-family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Lewy body disease

Most Recent Events

  • 28 Sep 2022 KeifeRx plans a phase III trial for Lewy body disease (KeifeRx pipeline; September 2022)
  • 29 May 2020 KeifeRx has an exclusive option to license to the intellectual property from Georgetown University
  • 08 Oct 2019 Georgetown University has patent protection for tyrosine kinase inhibitors for the treatment of neurodegenerative diseases in USA and Australia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top